M&A Deal Summary

Shionogi & Co Acquires C&O Pharmaceutical Technology Holdings

On August 1, 2011, Shionogi & Co acquired healthcare services company C&O Pharmaceutical Technology Holdings from CMIA Capital Partners Pte and Zana Capital Pte for 185M USD

Acquisition Highlights
  • This is Shionogi & Co’s 1st transaction in the Healthcare Services sector.
  • This is Shionogi & Co’s 2nd largest (disclosed) transaction.
  • This is Shionogi & Co’s 2nd transaction in China.

M&A Deal Summary
Date 2011-08-01
Target C&O Pharmaceutical Technology Holdings
Sector Healthcare Services
Buyer(s) Shionogi & Co
Sellers(s) CMIA Capital Partners Pte
Zana Capital Pte
Deal Type Add-on Acquisition
Deal Value 185M USD

Target

C&O Pharmaceutical Technology Holdings

Tsim Sha Tsui, China
website
C&O is an integrated pharmaceutical group in China. Its activities span research & development, manufacturing, and marketing and distribution of C&O and third party brand products.

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Shionogi & Co

Osaka, Japan

website

Category Company
Founded 1878
Sector Manufacturing
Employees5,693
Revenue 335.1B JPY (2022)
DESCRIPTION

Shionogi & Co is a pharmaceutical company develops crestor, medical supply and brand name also uses Shionogi. Shionogi was founded in 1878 and is based in Osaka, Japan.

DEAL STATS #
Overall 2 of 3
Sector (Healthcare Services) 1 of 1
Type (Add-on Acquisition) 2 of 3
Country (China) 2 of 2
Year (2011) 2 of 2
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-08-01 C & O Pharmaceutical Technology

Tsim Sha Tsui, China

A fully integrated pharmaceutical company with strong R&D, manufacturing and distribution businesses. The Company is involved in the development, manufacture and marketing of C&O branded drugs as well as in the distribution of third-party pharmaceutical products throughout China.

Buy $185M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-05-26 Tetra Therapeutics

Grand Rapids, Michigan, United States

Tetra Therapeutics is a clinical-stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from Fragile X syndrome, Alzheimer's disease, traumatic brain injury, and other brain disorders. Tetra Therapeutics is based in Grand Rapids, Michigan.

Buy -

Seller(S) 2

SELLER

CMIA Capital Partners Pte

Singapore, Singapore

Investor Investor Investor

website

Category Growth Capital Firm
Founded 2003
PE ASSETS 1.0B USD
Size Middle-Market
Type Sector Agnostic
DESCRIPTION

CMIA Capital Partners is a private equity firm focused on investing in mid-sized businesses located in China and Southeast Asia. Sectors of interest include agribusiness, automotive, environmental engineering, healthcare & medical equipment, industrial materials, real estate, and consumer products. CMIA Capital was formed in 2003 and has offices in Singapore and Hong Kong and China.

DEAL STATS #
Overall 3 of 4
Sector (Healthcare Services) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (China) 2 of 3
Year (2011) 2 of 2
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-02-28 Yingli International

Singapore, Singapore

Yingli International is Chongqing's leading commercial real estate company. Yingli has developed and owns Grade A commercial buildings in Chongqing's financial district, it also has been successful in old city regeneration or reconstruction, which is a key competitive advantage given Chongqing's ancient heritage.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-05-01 Haikui Seafood AG

Fujian, China

Haikui Seafood AG is a seafood company. Haikui's principal processed seafood products include frozen seafood (e.g., fish, shrimp, and crab), chilled seafood (e.g., crab meat, crab cakes, and breaded oysters), fresh seafood and canned seafood. Haikui Seafood was founded in 1993 and is based in Fujian, China.

Sell -
SELLER

Zana Capital Pte

Shanghai, China

Investor Investor Investor Investor

website

Category Private Equity Firm
PE ASSETS 700M USD
Size Middle-Market
Type Sector Agnostic
DESCRIPTION

Zana Capital is a China-focused private equity firm that targets growth equity investments in mid-sized businesses valued from $100 to $500 million (US). Zana generally looks to invest in companies with 'favorable macroeconomic fundamentals for that region, industry or sector', 'favorable governmental policies', strong management, stable cost structures, and sustainable pricing. Broad sectors of interest include pharmaceuticals, logistics, manufacturing, consumer, mining, and environmental engineering. Zana has offices in Shanghai, Chongqing and Singapore.

DEAL STATS #
Overall 3 of 4
Sector (Healthcare Services) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (China) 1 of 2
Year (2011) 2 of 2
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-02-28 Yingli International

Singapore, Singapore

Yingli International is Chongqing's leading commercial real estate company. Yingli has developed and owns Grade A commercial buildings in Chongqing's financial district, it also has been successful in old city regeneration or reconstruction, which is a key competitive advantage given Chongqing's ancient heritage.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-05-01 Haikui Seafood AG

Fujian, China

Haikui Seafood AG is a seafood company. Haikui's principal processed seafood products include frozen seafood (e.g., fish, shrimp, and crab), chilled seafood (e.g., crab meat, crab cakes, and breaded oysters), fresh seafood and canned seafood. Haikui Seafood was founded in 1993 and is based in Fujian, China.

Sell -
Mergr

Product

Company

Legal